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Table. Clinical Outcomes Through 4 Years
0w1 Year 1w4 Year(s) 0w4 Years
FIREHAWK
n[227
CoCr-EES
n[231 Log-rank p
FIREHAWK
n[226
CoCr-EES
n[229 Log-rank p
FIREHAWK
n[227
CoCr-EES
n[231 Log-rank p
TLF, % (n) 2.2 (5) 2.2 (5) 0.98 2.2 (5) 4.0 (9) 0.30 4.4 (10) 6.1 (14) 0.43
PoCE, % (n) 3.5 (8) 7.3 (17) 0.07 5.8 (13) 7.9 (18) 0.38 9.2 (21) 15.1 (35) 0.053
Death, % (n) 0.4 (1) 0.9 (2) 0.57 1.8 (4) 1.7 (4) 0.99 2.2 (5) 2.6 (6) 0.78
Cardiac Death, % (n) 0.4 (1) 0 (0) 0.32 0.4 (1) 0.4 (1) 0.99 0.9 (2) 0.4 (1) 0.56
MI, % (n) 1.3 (3) 2.2 (5) 0.49 0 (0) 1.3 (3) 0.08 1.3 (3) 3.5 (8) 0.14
Q Wave MI 0 (0) 0 (0) N/A 0 (0) 0.4 (1) 0.32 0 (0) 0.4 (1) 0.32
Non Q Wave MI 1.3 (3) 2.2 (5) 0.49 0 (0) 0.9 (2) 0.16 1.3 (3) 3.1 (7) 0.21
TV-MI 1.3 (3) 1.7 (4) 0.72 0 (0) 0.9 (2) 0.16 1.3 (3) 2.6 (6) 0.33
Any Revascularization, % (n) 1.8 (4) 4.8 (11) 0.07 4.5 (10) 6.2 (14) 0.43 6.2 (14) 11.0 (25) 0.07
iTLR, % (n) 0.4 (1) 0.4 (1) 0.99 1.8 (4) 3.5 (8) 0.16 2.2 (5) 4.0 (9) 0.33
Deﬁnite/Probable ST, % (n) 0 (0) 0 (0) N/A 0 (0) 0.4 (1) 0.32 0 (0) 0.4 (1) 0.32
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outcomes.
METHODS A total of 458 patients (vessel size between 2.25w4.0mm
and lesion length  24mm) were enrolled in the TARGET I RCT. The
primary non-inferiority endpoint was in-stent late lumen loss (LLL) at
9 months. Secondary endpoints were target lesion failure (TLF), a
composite of cardiac death, target vessel myocardial infarction (TV-
MI), or ischemia-driven target lesion revascularization (iTLR), and
patient-oriented composite endpoint (PoCE), a composite of all death,
all MI, or any repeat revascularization. Clinical follow-up (f/u) was
scheduled at 1 month, 6 and 12 months, and annually up to 5 years for
all enrolled patients. All adverse clinical events were adjudicated by
an independent committee.
RESULTS Previous reports have demonstrated FIREHAWK stent was
non-inferior to CoCr-EES for the primary endpoint of 9-month in-stent
LLL (0.130.24 mm vs. 0.130.18 mm, p for non-inferiority <0.0001),
and the two groups had similar clinical outcomes at 1 year. 445 (97.2%)
patients completed 4-year clinical f/u. There were still no signiﬁcant
differences between groups up to 4 years in terms of any composite
endpoints or individual components (Table). However, a landmark
analysis at 1 year showed non-signiﬁcant trends of lower incidences of
MI (0% vs. 1.3%, log-rank p¼0.08) and iTLR (1.8% vs. 3.5%, log-rank
p¼0.16) in favoring FIREHAWK group between 1 year and 4 years.
Furthermore, the 4-year rate of PoCE was 9.2% in FIREHAWK group
and 15.1% in CoCr-EES group, respectively, with a borderline differ-
ence (log-rank p¼0.053). No deﬁnite/probable stent thrombosis (ST)
was documented in FIREHAWK group through 4 years.
CONCLUSIONS In TARGET I RCT, the 4-year f/u results conﬁrmed
that the novel FIREHAWK stent had a durable safety and efﬁcacy
proﬁle, which was comparable to the best-in-class CoCr-EES in single
de novo coronary lesions. (ClinicalTrials.gov Identiﬁer: NCT01196819)
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BACKGROUND A non-inferiority study evaluating the long-term
safety and effectiveness of the Elixir DESyne BD Novolimus Eluting
Coronary Stent System (NECSS), a Co-Cr stent with a biodegradablepolymer compared to the control Endeavor Zotarolimus Eluting Cor-
onary Stent System (ZECSS) (Medtronic, Santa Rosa, CA).
METHODS 149 patients were randomized 3:1, either to the DESyne BD
NECSS or to the Endeavor ZECSS. Patients were analyzed for the pri-
mary endpoint (non-inferiority and superiority) of in-stent late lumen
loss (LLL) assessed by qualitative coronary angiography (QCA) at 6
months. Secondary endpoints were evaluated at 1, 6, 9, and 12 months
and annually through 5 years, and included a device-orientated
composite endpoint (DoCE) deﬁned as: cardiac death, target vessel
MI, clinically-indicated target lesion revascularization (TLR); clini-
cally-indicated target vessel revascularization (TVR); and stent
thrombosis. Lesions were also evaluated for 6-month angiographic
endpoints including: in-segment LLL, percent diameter stenosis,
post-procedure minimal lumen diameter, and angiographic binary
restenosis (ABR) (50%). A subset of patients underwent 6-month
intravascular ultrasound (IVUS) evaluation.
RESULTS The study met the primary endpoint demonstrating both
non-inferiority and superiority of the DESyne BD NECSS compared to
the control (0.120.15 vs 0.670.47, p<0.001). Six-month in-stent
ABR was signiﬁcantly lower for DESyne BD (0% vs 7.9%, p¼0.003).
Excellent clinical results were demonstrated for both devices with
sustained low clinical event rates observed through 36 months
(Table 1). Long-term clinical results through 48 months will be
presented.
CONCLUSIONS The DESyne BD NECSS demonstrated both non-infe-
riority and superiority over Endeavor for in-stent late lumen loss at 6
months. Clinical events remained low through 36 months; clinical
results through 48 months will be presented.
Table 1. Angiographic, IVUS and Clinical ResultsDESyne BD Endeavor p-valueAngiographic ResultsBaseline RVD (post-procedure) 3.00þ0.37 3.08þ0.35 0.21
6 month angiographic/IVUSIn-stent Late Lumen Loss 0.12þ0.15 0.67þ0.47 <0.001
% neointimal volume 3.6þ4.2 20.7þ14.2 <0.001
Clinical Results6-month DoCE (%) 2.7 3.2 1.00Clinically-indicated TLR 1.8 3.2 0.5212 month DoCE (%) 2.7 3.2 1.00Clinically-indicated TLR 1.8 3.2 1.5224 month DoCE (%) 2.7 3.2 1.00Clinically-indicated TLR 1.8 3.2 1.5236 month DoCE (%) 5.4 6.5 0.68Clinically-indicated TLR 2.7 6.5 0.30CATEGORIES CORONARY: Stents: Drug-Eluting
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